This site has been produced by Kite, a Gilead Company

Follow-up

Follow-upAfter the monitoring period is over, your healthcare team will arrange follow-up appointments and any ongoing care you may need.

These appointments are to monitor your overall health and may include routine tests such as blood tests. You may undergo assessments such as PET scan or CT scan for your healthcare team to understand how well your cancer is responding to treatment.

If necessary, your healthcare team might also arrange weekly phone calls with you. If you have any questions during this time you should contact your healthcare team directly via phone or email.

It’s a good idea to keep a note of how you’re feeling within ‘Your Treatment Journal’, so that you can discuss any changes with your healthcare team.

If you think you’re showing signs or symptoms of side effects, contact your healthcare team straight away. Do not treat your symptoms with over-the-counter medications or herbal/dietary supplements without the approval of your healthcare team.

Bullet
You will be given a Patient Alert Card after your infusion of CAR T. Carry this card with you at all times and show it to any healthcare professional you see.
Next Step

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

United Kingdom: Reporting of side effects

For patients residing in the United Kingdom, you can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of your medicine.

Republic of Ireland: Reporting of side effects

For patients residing in the Republic of Ireland, you can also report side effects directly via the HPRA website at www.hpra.ie. By reporting side effects, you can help provide more information on the safety of your medicine.

This site is a patient information resource, intended only for patients residing in the United Kingdom and Ireland who are being referred for or have been prescribed CAR T-cell therapy by their healthcare professional. This site has been developed and paid for by Kite, a Gilead Company.

This site has been produced by Kite, a Gilead Company

© 2023 Gilead Sciences, Inc. All rights reserved. KITE and the Kite logo are registered trademarks of Kite Pharma, Inc | GILEAD is a registered trademark of Gilead Sciences, Inc and its related companies

UK-UNB-3794 April 2023